Poland· PL-100505908
Anzupgo
A delgocitinib product containing delgocitinibum, registered in Poland by LEO Pharma A/S. The same ATC class is registered in 15 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Delgocitinib is registered in 15 of 19 countries.
Countries holding a registration under ATC D11AH11 (delgocitinib), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Delgocitinib · ATC D11AH11
15 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Delgocitinibum
- Manufacturer
- LEO Pharma A/S
- Country
- Poland (PL)
- ATC code
- D11AH11
- ATC class
- Delgocitinib
- Defined daily dose
- 40 mg, T
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991584474
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Delgocitinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaANZUPGOLEO Pharma A/S, Ballerup
- NorwayAnzupgoLEO PHARMA A/S (Danmark)
- United StatesAnzupgoLEO Pharma, Inc
- FranceANZUPGO 20 mg/g, crèmeLEO PHARMA A/S (DANEMARK)
- SwitzerlandAnzupgo
- IcelandAnzupgoLEO Pharma A/S*
- NetherlandsAnzupgo 20 mg/g crèmeLeo Pharma A/S
- SwedenAnzupgo 20 mg/g KrämLEO Pharma A/S
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Anzupgo
- Iceland · Anzupgo
- Liechtenstein · Anzupgo
- Norway · Anzupgo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/59608526-d898-451b-b064-9839a072ad09 GET /v1/drugs/59608526-d898-451b-b064-9839a072ad09?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Krem",
"source": "urpl",
"strength": "20 mg/g",
"packaging": "05909991584474 ¦ Rpz ¦ EU/1/24/1851/001 ¦ 158203\n1 tuba 15 g\nRpz ¦ EU/1/24/1851/002 ¦ 158204\n1 tuba 60 g",
"substance": "Delgocitinibum 20 mg/g",
"common_name": "Delgocitinibum",
"pl_product_id": "100505908",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about delgocitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.